Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$4 Mln
P/E Ratio
--
P/B Ratio
6.24
Industry P/E
--
Debt to Equity
0.19
ROE
-1.61 %
ROCE
-156.46 %
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-31.91 Mln
EBITDA
$-39.77 Mln
Net Profit
$-51.04 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
NanoVibronix (NAOV)
| -20.65 | 21.18 | 13.61 | -37.58 | -59.41 | -52.81 | -- |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
NanoVibronix (NAOV)
| -48.42 | -77.18 | -51.54 | 36.11 | -73.19 | -21.30 | -22.52 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 12.93 | 10,562.04 | 12.43 | 12.69 | |
| 72.80 | 10,050.19 | 97.07 | 2.52 | |
| 163.74 | 8,847.72 | -- | -25.23 | |
| 299.78 | 11,550.00 | 278.74 | 3.65 |
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes... UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. It sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, Australia, India, and internationally. The company was incorporated in 2003 and is headquartered in Elmsford, New York. Read more
CEO & Director
Mr. Brian M. Murphy
CEO & Director
Mr. Brian M. Murphy
Headquarters
Elmsford, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of NanoVibronix Inc (NAOV) stood at $ 4 Mln as on 31-Dec-24
The share price of NanoVibronix Inc (NAOV) is $5.15 (NASDAQ) as of 25-Apr-2025 16:29 EDT. NanoVibronix Inc (NAOV) has given a return of -59.41% in the last 3 years.
NanoVibronix Inc (NAOV) has a market capitalisation of $ 4 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of NanoVibronix Inc (NAOV) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the NanoVibronix Inc (NAOV) and enter the required number of quantities and click on buy to purchase the shares of NanoVibronix Inc (NAOV).
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. It sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, Australia, India, and internationally. The company was incorporated in 2003 and is headquartered in Elmsford, New York.
The CEO & director of Mr. Brian M. Murphy. is NanoVibronix Inc (NAOV), and CFO & Sr. VP is Mr. Brian M. Murphy.
There is no promoter pledging in NanoVibronix Inc (NAOV).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,078
|
|
|
1,054
|
|
|
964
|
|
|
853
|
| NanoVibronix Inc. (NAOV) | Ratios |
|---|---|
|
Return on equity(%)
|
-160.56
|
|
Operating margin(%)
|
-138.82
|
|
Net Margin(%)
|
-144.84
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of NanoVibronix Inc (NAOV) was $0 Mln.
$-0.75
(
